Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

603 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients.
Vassilakopoulou M, Togun T, Dafni U, Cheng H, Bordeaux J, Neumeister VM, Bobos M, Pentheroudakis G, Skarlos DV, Pectasides D, Kotoula V, Fountzilas G, Rimm DL, Psyrri A. Vassilakopoulou M, et al. Among authors: fountzilas g. PLoS One. 2014 Jun 26;9(6):e99131. doi: 10.1371/journal.pone.0099131. eCollection 2014. PLoS One. 2014. PMID: 24968015 Free PMC article.
Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial.
Kosmidis P, Mylonakis N, Nicolaides C, Kalophonos C, Samantas E, Boukovinas J, Fountzilas G, Skarlos D, Economopoulos T, Tsavdaridis D, Papakostas P, Bacoyiannis C, Dimopoulos M. Kosmidis P, et al. Among authors: fountzilas g. J Clin Oncol. 2002 Sep 1;20(17):3578-85. doi: 10.1200/JCO.2002.12.112. J Clin Oncol. 2002. PMID: 12202657 Clinical Trial.
Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group.
Fountzilas G, Razis E, Tsavdaridis D, Karina M, Labropoulos S, Christodoulou C, Mavroudis D, Gogas H, Georgoulias V, Skarlos D. Fountzilas G, et al. Clin Breast Cancer. 2003 Jun;4(2):120-5. doi: 10.3816/cbc.2003.n.017. Clin Breast Cancer. 2003. PMID: 12864940
Adjuvant cytotoxic and endocrine therapy in pre- and postmenopausal patients with breast cancer and one to nine infiltrated nodes: five-year results of the Hellenic Cooperative Oncology Group randomized HE 10/92 study.
Fountzilas G, Stathopoulos G, Kouvatseas G, Polychronis A, Klouvas G, Samantas E, Zamboglou N, Kyriakou K, Adamou A, Pectasidis D, Ekonomopoulos T, Kalofonos HP, Bafaloukos D, Georgoulias V, Razis E, Koukouras D, Zombolas V, Kosmidis P, Skarlos D, Pavlidis N; Hellenic Cooperative Oncology Group. Fountzilas G, et al. Am J Clin Oncol. 2004 Feb;27(1):57-67. doi: 10.1097/01.coc.0000046121.51504.b9. Am J Clin Oncol. 2004. PMID: 14758135 Clinical Trial.
Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year--a Hellenic Cooperative Oncology Group study.
Gogas H, Bafaloukos D, Ioannovich J, Skarlos D, Polyzos A, Fountzilas G, Kalofonos HP, Aravantinos G, Tsoutsos D, Panagiotou P, Frangia K, Petrakopoulou T, Pectasides D; Hellenic Coperative Oncology Group. Gogas H, et al. Among authors: fountzilas g. Anticancer Res. 2004 May-Jun;24(3b):1947-52. Anticancer Res. 2004. PMID: 15274382 Free article. Clinical Trial.
Concomitant radiochemotherapy vs radiotherapy alone in patients with head and neck cancer: a Hellenic Cooperative Oncology Group Phase III Study.
Fountzilas G, Ciuleanu E, Dafni U, Plataniotis G, Kalogera-Fountzila A, Samantas E, Athanassiou E, Tzitzikas J, Ciuleanu T, Nikolaou A, Pantelakos P, Zaraboukas T, Zamboglou N, Daniilidis J, Ghilezan N. Fountzilas G, et al. Med Oncol. 2004;21(2):95-107. doi: 10.1385/MO:21:2:095. Med Oncol. 2004. PMID: 15299181 Clinical Trial.
Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG).
Fountzilas G, Christodoulou C, Tsavdaridis D, Kalogera-Fountzila A, Aravantinos G, Razis E, Kalofonos HP, Papakostas P, Karina M, Gogas H, Skarlos D. Fountzilas G, et al. Cancer Invest. 2004;22(5):655-62. doi: 10.1081/cnv-200032980. Cancer Invest. 2004. PMID: 15581045 Clinical Trial.
603 results